Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ZOC2019619 eye drops in primary open-angle glaucoma or ocular hypertension
CTR20231641Phase 2Active
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Jun 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ZOC2019619 in open-angle glaucoma (OAG) and ocular hypertension (7 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Change from baseline in mean diurnal intraocular pressure. Started Jun 2023; status: active.
02
Drugs
ZOC2019619
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on CTR20231641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231641.